Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Cell signaling research rings warning bells over an emerging cancer drug target

Researchers at the Babraham Institute have used their understanding of cellular signalling to highlight a pitfall in an emerging treatment for cancer and inflammation.

14 Sep 2020

CN Bio partners with Imperial College London to uncover therapeutic targets for alcoholic hepatitis

CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems to improve the accuracy and efficiency of drug discovery, today announced a collaboration with Imperial College London, a world-class research university.

10 Sep 2020

Optibrium’s peer-reviewed study highlights the value of deep learning to impute drug discovery data

Optibrium, leading providers of software and services for drug discovery, today announced a peer-reviewed publication, ‘Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data’, in the Journal of Chemical Information and Modeling.

10 Sep 2020

Novel drug could improve life expectancy and quality for patients with hard-to-treat cancers

The Sheffield researchers founded the spin-out Modulus Oncology with a team of experienced biotech entrepreneurs to fast-track the drug into clinical testing within two years.

9 Sep 2020

Insilico Medicine launches new system for COVID-19 basic and clinical research

Today Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, announced the launch of a new system for COVID-19 basic and clinical research.

9 Sep 2020

Metrion Biosciences strengthens global business development team

Metrion Biosciences today announced it has enhanced its business development capabilities, committed to supporting regions in the USA, Europe, and Japan.

From Metrion Biosciences Limited 8 Sep 2020

Study links brain astrocyte dysfunction to Parkinson’s disease pathology

A new study using induced pluripotent stem cell technology links astrocyte dysfunction to Parkinson’s disease pathology.

8 Sep 2020

Researchers to create integrated global platform for longevity biotechnology, aging research

Deep Longevity, Inc (DLI), a leader in artificial intelligence for aging and longevity research announced that it had entered into the agreement to be acquired by Regent Pacific to create the integrated global platform for longevity biotechnology and aging research.

4 Sep 2020

New approach can make immunotherapy effective against cancers

If cancer is a series of puzzles, a new study pieces together how several of those puzzles connect to form a bigger picture.

3 Sep 2020

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

Hydrophilic Vyon® plastics demonstrate outstanding performance for drug discovery applications

Porvair Sciences reports on testing that demonstrates how its hydrophilic Vyon® porous plastics exhibit outstanding performance in drug discovery applications due to the high hydrophilic void volume conversion of the materials’ pore structure after a special treatment process.

From Porvair Sciences Limited 2 Sep 2020

Manipulating 3D Printed Organoid Microenvironments

Organoids are 3-dimensional (3D) clusters of stem cells that come together and emulate the microenvironment within individual organs, whether that be liver, kidney, heart, gut or other specific organs.

From Manchester BIOGEL 28 Aug 2020

SARS discovery boots search for COVID-19 drugs

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19.

27 Aug 2020

Axol Bioscience appoints Liam Taylor as Chief Executive Officer

Axol Bioscience today announced the appointment of Liam Taylor as CEO. Liam will focus on maximizing its iPSC technologies, products, and services.

From Axol Bioscience Ltd 27 Aug 2020

Dotmatics announces the launch of Bioregister 2020.1

Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced the introduction of Bioregister 2020.1, the latest version of its web-based application for registering sequence-based, chemically modified and structure-less biological entities.

27 Aug 2020

New aging biomarkers to be presented at 7th annual ARDD conference

Deep Longevity, a global science-driven longevity and performance management company utilizing the latest advances in artificial intelligence and aging research will present new research and tools for tracking human biological aging at the 7th annual Aging Research and Drug Discovery (ARDD) conference.

25 Aug 2020

Highly expressed protein in lung cancer cells drives resistance to targeted therapies

A protein highly expressed in lung cancer cells drives resistance to targeted therapies, report researchers at the Medical University of South Carolina in the Journal of Thoracic and Cardiovascular Surgery.

25 Aug 2020

AI can expedite drug repurposing process for finding COVID-19 therapies, says GlobalData

Out of all the different approaches available to find new therapies to treat COVID-19, drug repurposing is one of the fastest and safest methods, as the drugs are already being used to treat other conditions therefore leading to fewer chances of adverse reactions.

21 Aug 2020